Merck’s Keytruda (pembrolizumab) Receives EU Approval for Resected Stage III Melanoma in Adults

 Merck’s Keytruda (pembrolizumab) Receives EU Approval for Resected Stage III Melanoma in Adults

Merck’s Keytruda (pembrolizumab) Receives EU Approval for Resected Stage III Melanoma in Adults

Shots:
  • The approval is based on P-III EORTC1325/KEYNOTE-054 trial assessing Keytruda (IV 200mg, q3w) as adjuvant therapy vs PBO, in 1,019 patients in ratio (1:1) with completely resected melanoma (stage IIIA [>1 mm lymph node metastasis], IIIB or IIIC
  • P-III EORTC1325/KEYNOTE-054 results: RFS@ 7mos. 44%, RFS@12, 18 mos. (76%, 72% vs 61%, 54%); BRAF positive tumors patients RFS @6 mos. (83% vs 73%)
  • Keytruda (pembrolizumab) 100 mg is a mAb serving as an anti-PD-1 therapy for the tumor cells blocking the interaction b/w PD-1 and its ligands (PD-L1 and PD-L2), and is evaluated in 850 trials in oncology

Click here to read full press release/ article | Ref: Merck & Co| Image: Fox Business

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post